Reduction of serum IGF-I levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and K-ras gene mutation

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Greco, Claudia ^a,b   Vitelli, Gaetano ^a   Vercillo, Giuseppe ^a   Vona, Rosa ^c   Giannarelli, Diana ^d   Sperduti, Isabella ^d   Pisani, Francesco ^e   Capoluongo, Ettore ^f   Petti, Maria Concetta ^e   Ameglio, Franco ^f  

^a Clinical Pathology   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Service of Biostatistics   (Italy)

^e Hematology Unit   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GENOMIC DNA; K RAS PROTEIN; MELPHALAN; PREDNISONE; SOMATOMEDIN C; VASCULOTROPIN; ALKYLATING AGENT; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE RAS; PARAPROTEINEMIA;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENES, RAS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; PARAPROTEINEMIAS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63849130567     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-35     Document Type: Article

References (51)

1. Biology and management of multiple myeloma. JR Berenson Ed, Humana Press New Jersey, USA 2004
2. Antiangiogenesis drug design: multiple pathways targeting tumour vasculature. H Zhong JP Bowen, Curr Med Chem 2006 13 849 862 10.2174/092986706776361085 16611071
3. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. T Shih C Lindley, Clin Ther 2006 28 1779 1802 10.1016/j.clinthera. 2006.11.015 17212999
4. Response to Thalidomide in multiple myeloma: impact of angiogenic factors. L Rosinol MT Cibeira M Segarra MC Cid X Filella M Aymerich M Rozman L Arenillas J Esteve J Blade E Montserrat, Cytokine 2004 26 145 148 10.1016/j.cyto.2004.02.002 15149630
5. Importance of the bone marrow microenvironment in inducine the angiogenic response in multiple myeloma. D Ribatti B Nico A Vacca, Oncogene 2006 25 4257 4266 10.1038/sj.onc.1209456 16518413
6. Bone marrow angiogenesis in multiple myeloma. A Vacca D Ribatti, Leukemia 2006 20 193 199 10.1038/sj.leu.2404067 16357836
7. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. S Kumar TE Witzig M Timm J Haug L Wellik TK Kimlinger PR Greipp SV Rajkumar, Blood 2004 104 1159 1165 10.1182/blood-2003-11-3811 15130943
8. Circulating angiogenic cytokines in multiple myeloma and related disorders. H Urba Ska-Rys A Wierzbowska T Robak, Eur Cytokine Netw 2003 14 40 51 12799213
9. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. C Ribas GW Colleoni MR Silva MJ Carregoza JO Bordin, Eur J Haematol 2004 73 311 317 10.1111/j.1600-0609.2004.00314.x 15458509
10. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. JH Choi MJ Ahn SJ Jang CK Park YW Park HS Oh YY Lee IY Choi IS Kim, Int J Hematol 2002 76 460 464 10.1007/BF02982812 12512841
11. Expression of Vascular Endothelial Growth Factor and its receptors in Multiple Myeloma and other hematopoietic malignancies. WT Bellamy, Semin Oncol 2001 28 551 559 10.1016/S0093-7754(01)90023-5 11740808
12. Vascular endothelial growth factor and its receptors in multiple myeloma. R Ria AM Roccaro F Merchionne A Vacca F Dammacco D Ribatti, Leukemia 2003 17 1961 1966 10.1038/sj.leu.2403076 14513045
13. Synergistic effects of vascular endothelial growth factor and basic fibriblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. F Goto K Goto K Weindel J Folkman, Lab Invest 1993 69 508 517 8246443
14. Synergistic effect of vascular endothelial growth factor and basic fibroblast factor on angiogenesis in vivo. T Asahara C Bauters LP Zheng S Takeshita S Bunting N Ferrara JF Symes Isner, Circulation 1995 92 9 Suppl 365 371 7586439
15. Insulin-like growth factors and neoplasia. MN Pollak ES Schernhammer SE Hankinson, Nat Rev Cancer 2004 4 505 518 10.1038/nrc1387 15229476
16. Insulin-like growth factor is a dual effector of multiple myeloma cell growth. NL Ge S Rudikoff, Blood 2000 96 2856 2861 11023522
17. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. AG Renehan M Zwahlen C Minder ST O'Dwyer SM Shalet M Egger, Lancet 2004 363 1346 1353 10.1016/S0140-6736(04)16044-3 15110491
18. Clinical utility of measurements of insulin-like growth factor 1. DR Clemmons, Nat Clin Pract Endoc Metab 2006 2 436 446 10.1038/ncpendmet0244
19. IGF-I mediated survival pathways in normal and malignant cells. RT Kurmasheva PJ Houghton, Biochem Biophys Acta 2006 1766 1 1 22 16844299
20. Role of insulin-like growth factor 1 receptor signalling in cancer. O Larsson A Girnita L Girnita, Br J Cancer 2005 92 2097 2101 10.1038/sj.bjc. 6602627 15956962
21. Regulation of cMyc expression.by PDGF through Rho GTPase. M Chiariello MJ Marinissen JS Gutkind, Nat Cell Biol 2001 3 580 586 10.1038/35078555 11389443
22. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. C Greco I D'Agnano G Vitelli R Vona M Marino M Mottolese C Zuppi E Capoluongo F Ameglio, Int J Immunopathol Pharm 2006 19 1 67 79
23. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumour angiogenesis. J Rak Y Mrtsuhashi L Bayko J Filmus T Sasazuki RS Kerbel, Cancer Res 1995 55 4575 4580 7553632
24. The association of k-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. N Ikeda Y Nakajima M Sho M Adachi CI Huang K Iki H Kanehiro M Hisanaga H Makano M Miyake, Cancer 2001 92 488 499 10.1002/1097-0142(20010801)92:3<488::AID-CNCR1347>3.0.CO;2-F 11505392
25. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. S Chi C Kitanaka K Noguchi K Noguchi T Mochizuki Y Nagashima M Shirouzu H Fujita M Yoshida W Chen A Asai M Himeno S Yokoyama Y Kuchino, Oncogene 1999 18 2281 2290 10.1038/sj.onc.1202538 10327074
26. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. BGM Durie SE Salmon, Cancer 1975 36 842 847 10.1002/1097-0142(197509) 36:3<842::AID-CNCR2820360303>3.0.CO;2-U 1182674
27. Rapid and sensitive nonradioactive detection of mutant K-ras genes via "enriched" PCR amplification. SM Kahn W Jang TA Culbertson IB Weinstein GM Williams N Tomita Z Ronai, Oncogene 1991 6 1079 1083 1676837
28. Cell surface overexpression of Galectin-3 and the presence of its ligand 90 k in the blood plasma as determinants of colon neoplastic lesions. C Greco M Cosimelli R Vona M Cosimelli P Matarrese E Straface P Scordati D Giannarelli V Casale D Assisi M Mottolese A Moles W Malorni, Glycobiol 2004 14 783 792 10.1093/glycob/cwh092
29. High incidence of N and K- Ras activating utations in multiple myeloma and primary plasma cell leukemia at diagnosis. S Bezieau MC Devilder H Avet-Loiseau MP Mellerin D Puthier E Pennarun MJ Rapp JL Harousseau JP Moisan R Bataille, Hum Mutat 2001 18 212 224 10.1002/humu.1177 11524732
30. Downstream effectors of oncogenic ras in multiple myeloma cells. L Hu Y Shi J Hsu J Gera B Van Ness A Lichtenstein, Blood 2003 101 3126 3135 10.1182/blood-2002-08-2640 12515720
31. Angiogenesis in multiple myeloma. C Jakob J Sterz I Zavrski U Heider L Kleeberg C Fleissner M Kaiser O Sezer, Eur J Cancer 2006 42 1581 1590 10.1016/j.ejca.2006.02.017 16797965
32. VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. R Ria A Vacca F Russo T Cirulli M Massaia P Tosi M Cavo D Guidolin D Ribatti F Dammacco, Thromb Haemost 2005 92 6 1438 1445
33. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basis fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. MG Alexandrakis FH Passam A Boula A Christophoridou G Aloizos P Roussou DS Kyriakou, Ann Hematol 2003 82 19 23 12574959
34. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. E Hatjiharissi E Terpos M Papaioannou C Hatjileontis V Kaloutsi G Galaktidou G Gerotziafas J Christakis K Zervas, Hematol Oncol 2004 22 159 168 10.1002/hon.738 15991268
35. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. MG Alexandrakis FH Passam A Sfiridaki CA Pappa JA Moschandrea E Kandidakis G Tsirakis DS Kyriakou, Int J Biol Markers 2004 19 1 52 57 15077927
36. Overview of the IGF-I system. P Cohen, Horm Res 2006 65 3 8 10.1159/000090640 16508327
37. Regulation of apoptosis by insulin-like growth factor (IGF)-I. R Kooijman, Cytokine Growth Factor Rev 2006 17 305 323 10.1016/j.cytogfr.2006.02. 002 16621671
38. Cross-talk between IGF-I and TGF-beta signaling pathways. D Danielpour K Song, Cytokine Growth Factor Rev 2006 17 59 74 10.1016/j.cytogfr.2005.09.007 16297654
39. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. T Standal M Borset S Lenhoff F Wisloff B Stordal A Sundan A Waage C Seidel, Blood 2002 100 3925 3929 10.1182/blood-2002-05-1406 12393395
40. Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone. A Hrycek A Gruszka, Arch Med Res 2006 37 74 78 10.1016/j.arcmed.2005.04.015 16314190
41. Transformation of a MGUS to overt multiple myeloma: the possibile role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-I). A Tucci S Bonadonna C Cattaneo M Ungari A Giustina R Giuseppe, Leukemia Lymphoma 2003 44 543 545 10.1080/1042819021000037895 12688330
42. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease. S Molica G Vitelli R Mirabelli G Digiesi D Giannarelli A Cuneo D Ribatti A Vacca, Eur J Haematol 2006 76 51 57 10.1111/j.1600-0609.2005.00553.x 16343271
43. Pro- inflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. S Da Lee C Yang Huang W Tong Shu TH Chen JA Lin HH Hsu CS Lin CJ Liu WW Kuo LM Chen, Clin Chim Acta 2006 370 50 56 10.1016/j.cca.2006. 01.012 16793032
44. Regulation of MDMX expression by mitogenic signalling. DM Gilkes Y Pan D Coppola T Yeatman GW Reuther J Chen, Mol Cell Biol 2008 28 1999 2010 18172009 10.1128/MCB.01633-07
45. Role of growth factors in pancreatic cancer. M Korc, Surg Oncol Clin N Am 1998 7 25 41 9443985
46. Molecular prognostic markers in pancreatic cancer. P Ghaneh A Kawesha JD Evans JP Neoptolemos, J Hepatob Pancr Surg 2002 9 1 11 10.1007/s005340200000
47. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. J Frystyk, Growth Horm IGF Res 2004 14 337 375 10.1016/j.ghir.2004.06.001 15336229
48. Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease. E Conti F Crea F Andreotti, Circulation 2003 107 20 e190 e192 12778905
49. Association between serum free IGF-I and IGFBP-3 levels in type-I diabetes patients affected with associated autoimmune diseases or diabetic complications. E Capoluogo D Pitocco C Santocito P Concolino SA Santini A Manto P Lulli G Ghirlanda C Zuppi F Ameglio, Eur Cytokine Netw 2006 17 167 174 17194636
50. IGF-I system, Vitamin D and blood pressure relationships. E Capoluongo C Zuppi F Ameglio, Cytokine 2007 37 183 184 10.1016/j.cyto.2007.03.014
51. Insulin-like growth factor I (CA) repeats are associated with higher melanomas Breslow index but not associated with the presence of the melanoma. A pilot study. C Santonocito A Paradisi R Capizzi P Concolino MM Lavieri SL Silveri D De Luca C Catricala A Di Carlo C Zuppi F Ameglio E Capoluongo, Clin Chim Acta 2008 390 104 109 10.1016/j.cca.2008.01.006 18237549